Other biological agent

BIOLOGICAL2 trials

Sponsors

Takeda, University of Athens

Conditions

Colitis, UlcerativeCrohn's DiseaseInflammationRheumatoid Arthritis

Unknown Phase

OTIS Vedolizumab Pregnancy Exposure Registry

CompletedNCT02678052

TakedaColitis, Ulcerative, Crohn's Disease

Start: 2015-12-01End: 2022-07-31Updated: 2024-10-08

Effects of Interleukin-6 Inhibition on Vascular, Endothelial and Left Ventricular Function in Rheumatoid Arthritis

University of AthensInflammation, Rheumatoid Arthritis

Start: 2017-10-27End: 2020-12-31Target: 60Updated: 2020-04-03

Related Papers

S751 The Vedolizumab Pregnancy Exposure Registry: An OTIS Pregnancy Study Update

The American Journal of Gastroenterology2022-10-011 citations

S792 The Vedolizumab Pregnancy Exposure Registry: An OTIS Pregnancy Study Update

The American Journal of Gastroenterology2021-10-012 citations

S0842 The Vedolizumab Pregnancy Exposure Registry: An OTIS Pregnancy Study Update

The American Journal of Gastroenterology2020-10-012 citations

Tocilizumab improves oxidative stress and endothelial glycocalyx: A mechanism that may explain the effects of biological treatment on COVID-19.

2020-08-1850 citations

717 The Vedolizumab Pregnancy Exposure Registry: An OTIS Pregnancy Study Update

The American Journal of Gastroenterology2019-10-015 citations

Differential effects of inhibition of interleukin 1 and 6 on myocardial, coronary and vascular function.

2019-03-1143 citations